AML Hub | Quarter One 2021 Update

Wednesday 7 April, 2021The AML Hub, founded in partnership with the European LeukemiaNet (ELN) and brought to you by Scientific Education Support (SES), provides up-to-date, unbiased material for healthcare professionals within the acute myeloid leukemia (AML) community, worldwide.

So far in Q1, the AML Hub has covered the educational theme, advances in frontline chemotherapy in AML, providing a summary of what was considered practice-changing in this setting from the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2020.

In 2021, the AML Hub continues to adapt to the virtual climate, remotely covering the 3rd European CAR T-cell Meeting, the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, and the National Comprehensive Cancer Network (NCCN) 2021 Virtual Annual Conference. The AML Hub provided a combination of live and on-demand social media coverage of key sessions and conducted interviews with experts in the field of AML.

The AML Hub is working hard to bring you the latest information regarding COVID-19 and its implications in the AML setting: a comprehensive summary of the preliminary COVID-19 vaccination recommendations for patients with hematologic malignancies has been published, based on expert opinion from the NCCN COVID-19 Vaccination Advisory Committee.

The AML Hub owes thanks to its sponsors—Roche Genentech (Gold), AbbVie (Silver), Amgen (Silver), Novartis (Silver), Bristol Myers Squibb (Bronze), Janssen Pharmaceuticals (Bronze), Jazz Pharmaceuticals (Bronze), Agios (Contributor), Gamida Cell (Contributor), Takeda (Contributor)—without whom the work would not be possible.

For more information on the AML Hub, please visit aml-hub.com. For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.

Distributed by https://pressat.co.uk/